NASDAQ:SAVA Cassava Sciences Q1 2025 Earnings Report $2.26 -0.04 (-1.53%) As of 11:03 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Cassava Sciences EPS ResultsActual EPS-$0.48Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACassava Sciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACassava Sciences Announcement DetailsQuarterQ1 2025Date5/8/2025TimeBefore Market OpensConference Call DateThursday, May 8, 2025Conference Call Time7:00AM ETUpcoming EarningsCassava Sciences' Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cassava Sciences Earnings HeadlinesCassava Sciences Releases New Corporate PresentationSeptember 8, 2025 | tipranks.comCassava Sciences, Inc.: Cassava Reports Q2 2025 Financials Results and Provides Business UpdateAugust 14, 2025 | finanznachrichten.deBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated billions of shares. Bill Gates sold 500,000 shares of Microsoft. Jeff Bezos filed to sell Amazon shares worth $4.8 billion. What is going on? One multi-millionaire believes they are preparing for a catastrophic event. But not a crash, bank run, or recession. It’s something we haven’t see in America for more than a century.September 19 at 2:00 AM | Banyan Hill Publishing (Ad)Cassava Sciences reports Q2 EPS (92c) vs 13c last yearAugust 14, 2025 | msn.comCassava Reports Q2 2025 Financials Results and Provides Business UpdateAugust 14, 2025 | globenewswire.comCassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical OfficerAugust 7, 2025 | globenewswire.comSee More Cassava Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cassava Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cassava Sciences and other key companies, straight to your email. Email Address About Cassava SciencesCassava Sciences (NASDAQ:SAVA) is a clinical-stage biopharmaceutical company focused on the development of novel therapies and diagnostics for Alzheimer’s disease and related neurodegenerative disorders. Headquartered in Austin, Texas, the company was originally founded as Pain Therapeutics in 1998 and rebranded to Cassava Sciences in 2017. Cassava’s research program centers on small molecules designed to address underlying mechanisms of neurodegeneration rather than solely targeting amyloid plaques or tau tangles. The company’s lead drug candidate, simufilam (formerly PTI-125), is a proprietary small molecule that aims to restore normal shape and function to the scaffolding protein filamin A, which has been implicated in impaired neuronal signaling and inflammation in Alzheimer’s patients. Simufilam is being evaluated in Phase 2b and Phase 3 clinical trials, with studies conducted across multiple sites in the United States and Australia. Cassava also maintains a pipeline of diagnostics, including exploratory blood-based biomarkers intended to detect pathogenic hallmarks of Alzheimer’s disease at earlier stages. Cassava Sciences is led by President and Chief Executive Officer Remi Barbier, who has guided the company’s strategic transition from pain management to neurodegenerative research. The executive team comprises professionals with backgrounds in neuroscience, clinical development, and regulatory affairs. Cassava’s board includes members with extensive experience in the biotechnology and pharmaceutical industries, supporting the company’s efforts to advance its pipeline and engage with regulatory authorities. With a mission to transform the treatment and diagnosis of Alzheimer’s disease, Cassava Sciences collaborates with academic institutions and contract research organizations to conduct its clinical studies. While the company’s primary activities are centered in North America and Australia, it seeks to establish partnerships and expand its research footprint globally as it progresses its therapeutic and diagnostic programs toward regulatory approval.View Cassava Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Wall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a Winner Upcoming Earnings Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025)Wells Fargo & Company (10/14/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
